Barclays (LON:BARC) analyst Steven Valiquette maintained a Hold rating on Align Tech (NASDAQ:ALGN) on Tuesday, setting a price target of $475, which is approximately 14.84% below the present share price of $557.77.
Valiquette expects Align Tech to post earnings per share (EPS) of $1.77 for the first quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Align Tech, with an average price target of $568.33.
The analysts price targets range from a high of $625 to a low of $475.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $734.14 million and a net profit of $177.07 million. The company's market cap is $43.98 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 1.4% and a 53.16% success rate.
Align Technology , Inc. engages in the manufacture, design, and marketing of global medical devices. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen and assist products, and vivera retainers along with training and ancillary products for treating malocclusion. The Scanner and Services segment comprises of intraoral scanning systems and additional services available with the intraoral scanners that provide digital alternatives to the traditional cast models. The company was founded by Zia Chishti, Brian Freyburger and Kelsey Wirth in March 1997 and is headquartered in San Jose, CA.